Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal

Journal of Hepatology

Volumn 58, Issue 5, 2013, Pages 1007-1019

  Machado, Mariana V ^a   Cortez Pinto, Helena ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Fibrosis; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Non invasive diagnosis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAFFEINE; CONTRAST MEDIUM; CYTOKERATIN 18; PHYTATE TC 99M;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CHEMISTRY; BLOOD SAMPLING; BREATH ANALYSIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; ELASTOGRAPHY; EXTRACELLULAR MATRIX; FATTY LIVER; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LIVING DONOR; MORBID OBESITY; MORTALITY; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

BIOPSY; DIAGNOSTIC TESTS, ROUTINE; DISEASE MANAGEMENT; FATTY LIVER; HUMANS; LIVER; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84876293750     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.11.021     Document Type: Review

References (145)

1. S. Bellentani, F. Scaglioni, M. Marino, and G. Bedogni Epidemiology of non-alcoholic fatty liver disease Dig Dis 28 2010 155 161
2. P. Angulo, J.C. Keach, K.P. Batts, and K.D. Lindor Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 1999 1356 1362
3. E. Fassio, E. Alvarez, N. Dominguez, G. Landeira, and C. Longo Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies Hepatology 40 2004 820 826
4. M.R. Charlton, J.M. Burns, R.A. Pedersen, K.D. Watt, J.K. Heimbach, and R.A. Dierkhising Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253
5. G. Musso, R. Gambino, M. Cassader, and G. Pagano Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 43 2011 617 649
6. A.A. Bravo, S.G. Sheth, and S. Chopra Liver biopsy N Engl J Med 344 2001 495 500
7. R.B. Merriman, L.D. Ferrell, M.G. Patti, S.R. Weston, M.S. Pabst, and B.E. Aouizerat Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease Hepatology 44 2006 874 880
8. G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, and L. Zenari Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 30 2007 1212 1218
9. A.L. Fracanzani, L. Valenti, E. Bugianesi, M. Andreoletti, A. Colli, and E. Vanni Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes Hepatology 48 2008 792 798
10. M.W. Pantsari, and S.A. Harrison Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase J Clin Gastroenterol 40 2006 633 635
11. Z.M. Younossi, T. Gramlich, C.A. Matteoni, N. Boparai, and A.J. McCullough Nonalcoholic fatty liver disease in patients with type 2 diabetes Clin Gastroenterol Hepatol 2 2004 262 265
12. G. Targher, C.P. Day, and E. Bonora Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease N Engl J Med 363 2010 1341 1350
13. M. Obika, and H. Noguchi Diagnosis and evaluation of nonalcoholic fatty liver disease Exp Diabetes Res 2012 2012 145754
14. N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, and K. Cusi The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609
15. L. McCormack, P. Dutkowski, A.M. El-Badry, and P.A. Clavien Liver transplantation using fatty livers: always feasible? J Hepatol 54 2011 1055 1062
16. V.E. de Meijer, B.T. Kalish, M. Puder, and J.N. Ijzermans Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection Br J Surg 97 2010 1331 1339
17. T. Poynard, V. Ratziu, S. Naveau, D. Thabut, F. Charlotte, and D. Messous The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis Comp Hepatol 4 2005 10
18. G. Lassailly, R. Caiazzo, A. Hollebecque, D. Buob, E. Leteurtre, and L. Arnalsteen Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity Eur J Gastroenterol Hepatol 23 2011 499 506
19. T. Poynard, G. Lassailly, E. Diaz, K. Clement, R. Caiazzo, and J. Tordjman Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data PLoS One 7 2012 e30325
20. G. Bedogni, S. Bellentani, L. Miglioli, F. Masutti, M. Passalacqua, and A. Castiglione The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population BMC Gastroenterol 6 2006 33
21. J.H. Kim, S.Y. Kwon, S.W. Lee, and C.H. Lee Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population Liver Int 31 2011 1600 1601
22. A. Gastaldelli, M. Kozakova, K. Hojlund, A. Flyvbjerg, A. Favuzzi, and A. Mitrakou Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population Hepatology 49 2009 1537 1544
23. G. Calori, G. Lattuada, F. Ragogna, M.P. Garancini, P. Crosignani, and M. Villa Fatty liver index and mortality: the Cremona study in the 15th year of follow-up Hepatology 54 2011 145 152
24. G. Bedogni, H.S. Kahn, S. Bellentani, and C. Tiribelli A simple index of lipid overaccumulation is a good marker of liver steatosis BMC Gastroenterol 10 2010 98
25. A. Kotronen, M. Peltonen, A. Hakkarainen, K. Sevastianova, R. Bergholm, and L.M. Johansson Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors Gastroenterology 137 2009 865 872
26. N. Wlazlo, M.M. van Greevenbroek, I. Ferreira, B. Bravenboer, and C.D. Stehouwer The diagnosis of non-alcoholic fatty liver disease Aliment Pharmacol Ther 35 2012 204 205 author reply 205-206
27. S.H. Saverymuttu, A.E. Joseph, and J.D. Maxwell Ultrasound scanning in the detection of hepatic fibrosis and steatosis BMJ 292 1986 13 15
28. M. Graif, M. Yanuka, M. Baraz, A. Blank, M. Moshkovitz, and A. Kessler Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease Invest Radiol 35 2000 319 324
29. B. Palmentieri, I. de Sio, V. La Mura, M. Masarone, R. Vecchione, and S. Bruno The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis Dig Liver Dis 38 2006 485 489
30. C.K. Ryan, L.A. Johnson, B.I. Germin, and A. Marcos One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation Liver Transpl 8 2002 1114 1122
31. H. Osawa, and Y. Mori Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes J Clin Ultrasound 24 1996 25 29
32. S. Ballestri, A. Lonardo, D. Romagnoli, L. Carulli, L. Losi, and C.P. Day Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD Liver Int 32 2012 1242 1252
33. S.B. Reeder, I. Cruite, G. Hamilton, and C.B. Sirlin Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy J Magn Reson Imaging 34 2011 729 749
34. S. Strauss, E. Gavish, P. Gottlieb, and L. Katsnelson Interobserver and intraobserver variability in the sonographic assessment of fatty liver AJR Am J Roentgenol 189 2007 W320 W323
35. C.C. Mottin, M. Moretto, A.V. Padoin, A.M. Swarowsky, M.G. Toneto, and L. Glock The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients Obes Surg 14 2004 635 637
36. M.F. Xia, H.M. Yan, W.Y. He, X.M. Li, C.L. Li, and X.Z. Yao Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method Obesity 20 2012 444 452
37. E. Solhjoo, F. Mansour-Ghanaei, R. Moulaei-Langorudi, and F. Joukar Comparison of portal vein doppler indices and hepatic vein doppler waveform in patients with nonalcoholic fatty liver disease with healthy control Hepat Mon 11 2011 740 744
38. L. Oguzkurt, T. Yildirim, D. Torun, F. Tercan, O. Kizilkilic, and E.A. Niron Hepatic vein Doppler waveform in patients with diffuse fatty infiltration of the liver Eur J Radiol 54 2005 253 257
39. A.R. Mohammadinia, K. Bakhtavar, N. Ebrahimi-Daryani, P. Habibollahi, M.R. Keramati, and S.M. Fereshtehnejad Correlation of hepatic vein Doppler waveform and hepatic artery resistance index with the severity of nonalcoholic fatty liver disease J Clin Ultrasound 38 2010 346 352
40. A. Balci, S. Karazincir, H. Sumbas, Y. Oter, E. Egilmez, and T. Inandi Effects of diffuse fatty infiltration of the liver on portal vein flow hemodynamics J Clin Ultrasound 36 2008 134 140
41. A. Mohammadi, M. Ghasemi-rad, H. Zahedi, G. Toldi, and T. Alinia Effect of severity of steatosis as assessed ultrasonographically on hepatic vascular indices in non-alcoholic fatty liver disease Med Ultrasonogr 13 2011 200 206
42. C. Fierbinteanu-Braticevici, I. Dina, A. Petrisor, L. Tribus, L. Negreanu, and C. Carstoiu Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis World J Gastroenterol 16 2010 4784 4791
43. J.E. Jacobs, B.A. Birnbaum, and M.A. Shapiro Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT AJR Am J Roentgenol 171 1998 659 664
44. S.H. Park, P.N. Kim, K.W. Kim, S.W. Lee, S.E. Yoon, and S.W. Park Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment Radiology 239 2006 105 112
45. M. Fishbein, F. Castro, S. Cheruku, S. Jain, B. Webb, and T. Gleason Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound J Clin Gastroenterol 39 2005 619 625
46. N.F. Schwenzer, F. Springer, C. Schraml, N. Stefan, J. Machann, and F. Schick Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance J Hepatol 51 2009 433 445
47. L.S. Szczepaniak, P. Nurenberg, D. Leonard, J.D. Browning, J.S. Reingold, and S. Grundy Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol 288 2005 E462 E468
48. S. McPherson, J.R. Jonsson, G.J. Cowin, P. O'Rourke, A.D. Clouston, and A. Volp Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered J Hepatol 51 2009 389 397
49. J. Boursier, and P. Cales Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int 32 2012 875 877
50. M. Sasso, M. Beaugrand, V. de Ledinghen, C. Douvin, P. Marcellin, and R. Poupon Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes Ultrasound Med Biol 36 2010 1825 1835
51. V. de Ledinghen, J. Vergniol, J. Foucher, W. Merrouche, and B. le Bail Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography Liver Int 32 2012 911 918
52. R.P. Myers, A. Pollett, R. Kirsch, G. Pomier-Layrargues, M. Beaton, and M. Levstik Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography Liver Int 32 2012 902 910
53. A.J. McCullough The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease Clin Liver Dis 8 2004 521 533 viii
54. O. Cheung, A. Kapoor, P. Puri, S. Sistrun, V.A. Luketic, and C.C. Sargeant The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome Hepatology 46 2007 1091 1100
55. G. Marchesini, E. Bugianesi, G. Forlani, F. Cerrelli, M. Lenzi, and R. Manini Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 37 2003 917 923
56. M.C. Ryan, A.M. Wilson, J. Slavin, J.D. Best, A.J. Jenkins, and P.V. Desmond Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease Diabetes Care 28 2005 1222 1224
57. P. Mofrad, M.J. Contos, M. Haque, C. Sargeant, R.A. Fisher, and V.A. Luketic Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values Hepatology 37 2003 1286 1292
58. A.E. Feldstein, A. Wieckowska, A.R. Lopez, Y.C. Liu, N.N. Zein, and A.J. McCullough Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study Hepatology 50 2009 1072 1078
59. A. Suzuki, J. Lymp, J.S. Sauver, P. Angulo, and K. Lindor Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis Liver Int 26 2006 1209 1216
60. K. Nomura, E. Yano, T. Shinozaki, and K. Tagawa Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups J Occup Health 46 2004 423 428
61. H. Kayadibi, M. Gultepe, B. Yasar, A.T. Ince, O. Ozcan, and O.M. Ipcioglu Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis Dig Dis Sci 54 2009 1764 1771
62. S.S. Kunde, A.J. Lazenby, R.H. Clements, and G.A. Abrams Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women Hepatology 42 2005 650 656
63. L.A. Adams, and A.E. Feldstein Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis J Dig Dis 12 2011 10 16
64. P.M. Gholam, L. Flancbaum, J.T. Machan, D.A. Charney, and D.P. Kotler Nonalcoholic fatty liver disease in severely obese subjects Am J Gastroenterol 102 2007 399 408
65. R. Haring, H. Wallaschofski, M. Nauck, M. Dorr, S.E. Baumeister, and H. Volzke Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels Hepatology 50 2009 1403 1411
66. N. Alkhouri, G. Morris-Stiff, C. Campbell, R. Lopez, T.A. Tamimi, and L. Yerian Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease Liver Int 32 2012 297 302
67. E.M. Zardi, I. De Sio, G. Ghittoni, B. Sadun, B. Palmentieri, and P. Roselli Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis? J Clin Gastroenterol 45 2011 59 63
68. G. Tarantino, P. Conca, F. Pasanisi, M. Ariello, M. Mastrolia, and A. Arena Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 21 2009 504 511
69. K. Suzuki, H. Kirikoshi, M. Yoneda, H. Mawatari, K. Fujita, and Y. Nozaki Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis Hepatol Res 40 2010 693 700
70. F. Moriyasu, H. Iijima, K. Tsuchiya, Y. Miyata, A. Furusaka, and T. Miyahara Diagnosis of NASH using delayed parenchymal imaging of contrast ultrasound Hepatol Res 33 2005 97 99
71. H. Iijima, F. Moriyasu, K. Tsuchiya, S. Suzuki, M. Yoshida, and M. Shimizu Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis Hepatol Res 37 2007 722 730
72. E. Bugianesi, U. Pagotto, R. Manini, E. Vanni, A. Gastaldelli, and R. de Iasio Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity J Clin Endocrinol Metab 90 2005 3498 3504
73. M.H. Jarrar, A. Baranova, R. Collantes, B. Ranard, M. Stepanova, and C. Bennett Adipokines and cytokines in non-alcoholic fatty liver disease Aliment Pharmacol Ther 27 2008 412 421
74. J.M. Hui, A. Hodge, G.C. Farrell, J.G. Kench, A. Kriketos, and J. George Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40 2004 46 54
75. M. Shimada, H. Kawahara, K. Ozaki, M. Fukura, H. Yano, and M. Tsuchishima Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis Am J Gastroenterol 102 2007 1931 1938
76. M. Lemoine, V. Ratziu, M. Kim, M. Maachi, D. Wendum, and F. Paye Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease Liver Int 29 2009 1431 1438
77. M.V. Machado, J. Coutinho, F. Carepa, A. Costa, H. Proenca, and H. Cortez-Pinto How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease Eur J Gastroenterol Hepatol 24 2012 1166 1172
78. G. Musso, R. Gambino, G. Biroli, M. Carello, E. Faga, and G. Pacini Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis Am J Gastroenterol 100 2005 2438 2446
79. J.W. Haukeland, Z. Konopski, P. Linnestad, S. Azimy, E. Marit Loberg, and T. Haaland Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease Scand J Gastroenterol 40 2005 1469 1477
80. A. Wieckowska, B.G. Papouchado, Z. Li, R. Lopez, N.N. Zein, and A.E. Feldstein Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis Am J Gastroenterol 103 2008 1372 1379
81. G. Kirovski, C. Dorn, H. Huber, L. Moleda, C. Niessen, and H. Wobser Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation Exp Mol Pathol 91 2011 780 783
82. J.W. Haukeland, J.K. Damas, Z. Konopski, E.M. Loberg, T. Haaland, and I. Goverud Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2 J Hepatol 44 2006 1167 1174
83. J.M. Hui, G.C. Farrell, J.G. Kench, and J. George High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD Hepatology 39 2004 1458 1459
84. G. Targher Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease J Hepatol 45 2006 879 881 author reply 881-872
85. E. Zimmermann, R. Anty, J. Tordjman, A. Verrijken, P. Gual, and A. Tran C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients J Hepatol 55 2011 660 665
86. M. Yoneda, T. Uchiyama, S. Kato, H. Endo, K. Fujita, and K. Yoneda Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH) BMC Gastroenterol 8 2008 53
87. A.J. Sanyal, C. Campbell-Sargent, F. Mirshahi, W.B. Rizzo, M.J. Contos, and R.K. Sterling Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 120 2001 1183 1192
88. A. Wieckowska, N.N. Zein, L.M. Yerian, A.R. Lopez, A.J. McCullough, and A.E. Feldstein In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease Hepatology 44 2006 27 33
89. Y. Yilmaz, E. Dolar, E. Ulukaya, S. Akgoz, M. Keskin, and M. Kiyici Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis World J Gastroenterol 13 2007 837 844
90. R.R. Mitry, R. De Bruyne, A. Quaglia, R.D. Hughes, and A. Dhawan Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers Hepatology 46 2007 2047 2048 author reply 2048
91. Z.M. Younossi, M. Jarrar, C. Nugent, M. Randhawa, M. Afendy, and M. Stepanova A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH) Obes Surg 18 2008 1430 1437
92. D.L. Diab, L. Yerian, P. Schauer, S.R. Kashyap, R. Lopez, and S.L. Hazen Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients Clin Gastroenterol Hepatol 6 2008 1249 1254
93. R. Malik, M. Chang, K. Bhaskar, I. Nasser, M. Curry, and D. Schuppan The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease J Gastroenterol Hepatol 24 2009 564 568
94. M. Tsutsui, N. Tanaka, M. Kawakubo, Y. Sheena, A. Horiuchi, and M. Komatsu Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels J Clin Gastroenterol 44 2010 440 447
95. G.V. Papatheodoridis, E. Hadziyannis, E. Tsochatzis, A. Georgiou, G. Kafiri, and D.G. Tiniakos Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease J Clin Gastroenterol 44 2010 e87 e95
96. T.I. Tamimi, H.M. Elgouhari, N. Alkhouri, L.M. Yerian, M.P. Berk, and R. Lopez An apoptosis panel for nonalcoholic steatohepatitis diagnosis J Hepatol 54 2011 1224 1229
97. J. Shen, H.L. Chan, G.L. Wong, P.C. Choi, A.W. Chan, and H.Y. Chan Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers J Hepatol 56 2012 1363 1370
98. D. Joka, K. Wahl, S. Moeller, J. Schlue, B. Vaske, and M.J. Bahr Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis Hepatology 55 2012 455 464
99. M. Gulsen, Z. Yesilova, S. Bagci, A. Uygun, A. Ozcan, and C.N. Ercin Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease J Gastroenterol Hepatol 20 2005 1448 1455
100. Y. Yilmaz, E. Ulukaya, O.O. Gul, M. Arabul, C.B. Gul, and O. Atug Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease Clin Biochem 42 2009 802 807
101. J.B. Dixon, P.S. Bhathal, and P.E. O'Brien Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese Gastroenterology 121 2001 91 100
102. N.A. Palekar, R. Naus, S.P. Larson, J. Ward, and S.A. Harrison Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease Liver Int 26 2006 151 156
103. T. Poynard, V. Ratziu, F. Charlotte, D. Messous, M. Munteanu, and F. Imbert-Bismut Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease BMC Gastroenterol 6 2006 34
104. Z.M. Younossi, S. Page, N. Rafiq, A. Birerdinc, M. Stepanova, and N. Hossain A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis Obes Surg 21 2011 431 439
105. R. Anty, A. Iannelli, S. Patouraux, S. Bonnafous, V.J. Lavallard, and M. Senni-Buratti A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients Aliment Pharmacol Ther 32 2010 1315 1322
106. 13C-caffeine breath test J Gastroenterol Hepatol 26 2011 1411 1416
107. 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis J Clin Gastroenterol 42 2008 408 412
108. P. Portincasa, I. Grattagliano, B.H. Lauterburg, V.O. Palmieri, G. Palasciano, and F. Stellaard Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis Clin Sci (Lond) 111 2006 135 143
109. M. Banasch, M. Ellrichmann, A. Tannapfel, W.E. Schmidt, and O. Goetze The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis Eur J Med Res 16 2010 258 264
110. M. Kikuchi, K. Tomita, T. Nakahara, N. Kitamura, T. Teratani, and R. Irie Utility of quantitative 99mTc-phytate scintigraphy to diagnose early-stage non-alcoholic steatohepatitis Scand J Gastroenterol 44 2009 229 236
111. K. Masuda, M. Ono, M. Fukumoto, A. Hirose, K. Munekage, and T. Ochi Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease Hepatol Res 42 2012 273 279
112. L.A. Adams, S. Sanderson, K.D. Lindor, and P. Angulo The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies J Hepatol 41 2005 132 138
113. M. Shimada, E. Hashimoto, H. Kaneda, S. Noguchi, and N. Hayashi Nonalcoholic steatohepatitis: risk factors for liver fibrosis Hepatol Res 24 2002 429 438
114. V. Tahan, B. Canbakan, H. Balci, F. Dane, H. Akin, and G. Can Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk Hepatogastroenterology 55 2008 1433 1438
115. A. Suzuki, P. Angulo, J. Lymp, D. Li, S. Satomura, and K. Lindor Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease Liver Int 25 2005 779 786
116. M. Yoneda, H. Mawatari, K. Fujita, K. Yonemitsu, S. Kato, and H. Takahashi Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage J Gastroenterol 42 2007 375 381
117. C.R. Lesmana, I. Hasan, U. Budihusodo, R.A. Gani, E. Krisnuhoni, and N. Akbar Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis J Dig Dis 10 2009 201 206
118. H. Sakugawa, T. Nakayoshi, K. Kobashigawa, T. Yamashiro, T. Maeshiro, and S. Miyagi Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease World J Gastroenterol 11 2005 255 259
119. V. Ratziu, P. Giral, and F. Charlotte Liver fibrosis in overweight patients Gastroenterology 118 2000 1117 1123
120. W.M. Rosenberg, M. Voelker, R. Thiel, M. Becka, A. Burt, and D. Schuppan Serum markers detect the presence of liver fibrosis: a cohort study Gastroenterology 127 2004 1704 1713
121. I.N. Guha, J. Parkes, P. Roderick, D. Chattopadhyay, R. Cross, and S. Harris Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers Hepatology 47 2008 455 460
122. V. Ratziu, J. Massard, F. Charlotte, D. Messous, F. Imbert-Bismut, and L. Bonyhay Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease BMC Gastroenterol 6 2006 6
123. P. Angulo, J.M. Hui, G. Marchesini, E. Bugianesi, J. George, and G.C. Farrell The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD Hepatology 45 2007 846 854
124. S.A. Harrison, D. Oliver, H.L. Arnold, S. Gogia, and B.A. Neuschwander-Tetri Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease Gut 57 2008 1441 1447
125. H. Fujii, M. Enomoto, W. Fukushima, A. Tamori, H. Sakaguchi, and N. Kawada Applicability of BARD score to Japanese patients with NAFLD Gut 58 2009 1566 1567 author reply 1567
126. G. Ruffillo, E. Fassio, E. Alvarez, G. Landeira, C. Longo, and N. Dominguez Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease J Hepatol 54 2011 160 163
127. S. McPherson, S.F. Stewart, E. Henderson, A.D. Burt, and C.P. Day Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease Gut 59 2010 1265 1269
128. L.A. Adams, J. George, E. Bugianesi, E. Rossi, W.B. De Boer, and D. van der Poorten Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease J Gastroenterol Hepatol 26 2011 1536 1543
129. P. Cales, F. Laine, J. Boursier, Y. Deugnier, V. Moal, and F. Oberti Comparison of blood tests for liver fibrosis specific or not to NAFLD J Hepatol 50 2009 165 173
130. S. Gaia, S. Carenzi, A.L. Barilli, E. Bugianesi, A. Smedile, and F. Brunello Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis J Hepatol 54 2011 64 71
131. M. Yoneda, M. Yoneda, K. Fujita, M. Inamori, M. Tamano, and H. Hiriishi Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD) Gut 56 2007 1330 1331
132. V.W. Wong, J. Vergniol, G.L. Wong, J. Foucher, H.L. Chan, and B. Le Bail Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease Hepatology 51 2010 454 462
133. M. Lupsor, R. Badea, H. Stefanescu, M. Grigorescu, A. Serban, and C. Radu Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis J Gastrointest Liver Dis 19 2010 53 60
134. M. Yoneda, M. Yoneda, H. Mawatari, K. Fujita, H. Endo, and H. Iida Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD) Dig Liver Dis 40 2008 371 378
135. R. Kumar, A. Rastogi, M.K. Sharma, V. Bhatia, P. Tyagi, and P. Sharma Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation Dig Dis Sci 58 2013 265 274
136. V. de Ledinghen, J. Vergniol, J. Foucher, F. El-Hajbi, W. Merrouche, and V. Rigalleau Feasibility of liver transient elastography with FibroScan using a new probe for obese patients Liver Int 30 2010 1043 1048
137. M. Friedrich-Rust, H. Hadji-Hosseini, S. Kriener, E. Herrmann, I. Sircar, and A. Kau Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis Eur Radiol 20 2010 2390 2396
138. M. Lupsor, R. Badea, H. Stefanescu, Z. Sparchez, H. Branda, and A. Serban Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results J Gastrointest Liver Dis 18 2009 303 310
139. H. Ebinuma, H. Saito, M. Komuta, K. Ojiro, K. Wakabayashi, and S. Usui Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with FibroScan((R)) J Gastroenterol 46 2011 1238 1248
140. M. Yoneda, K. Suzuki, S. Kato, K. Fujita, Y. Nozaki, and K. Hosono Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography Radiology 256 2010 640 647
141. M. Friedrich-Rust, D. Romen, J. Vermehren, S. Kriener, D. Sadet, and E. Herrmann Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD Eur J Radiol 81 2012 e325 331
142. H. Ochi, M. Hirooka, Y. Koizumi, T. Miyake, Y. Tokumoto, and Y. Soga Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases Hepatology 2012
143. M. Yin, J.A. Talwalkar, K.J. Glaser, A. Manduca, R.C. Grimm, and P.J. Rossman Assessment of hepatic fibrosis with magnetic resonance elastography Clin Gastroenterol Hepatol 5 2007 e1202
144. L. Huwart, C. Sempoux, E. Vicaut, N. Salameh, L. Annet, and E. Danse Magnetic resonance elastography for the noninvasive staging of liver fibrosis Gastroenterology 135 2008 32 40
145. V. Ratziu, S. Bellentani, H. Cortez-Pinto, C. Day, and G. Marchesini A position statement on NAFLD/NASH based on the EASL 2009 special conference J Hepatol 53 2010 372 384